Figure 5.

ATUX-8385 decreased SK-N-BE(2) tumor growth in vivo. SK-N-AS or SK-N-BE(2) cells were injected into the right flank of female athymic nude mice. When tumor volume reached 100 mm³, animals were randomized into groups of three to receive either vehicle, ATUX-3364, or ATUX-8385 (50 mg/kg). (A,B) Animals bearing SK-N-AS tumors (n = 7 in vehicle, n = 6 in ATUX-3364, n = 6 in ATUX-8385 treatment groups) were treated for 14 days. There was no significant difference in change in tumor volume or relative tumor growth with either compound. (C,D) Animals bearing SK-N-BE(2) tumors (n = 5 in vehicle, n = 6 in ATUX-3364, and n = 7 in ATUX-8385 treatment groups) were treated for 21 days. There was a significant decrease in tumor volume and relative tumor growth with ATUX-8385 treatment. Data are reported as mean fold change in tumor volume ± SEM. * p ≤ 0.05.